PRVB
Provention Bio Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Provention Bio, Inc. is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay or prevention of clinical type 1 diabetes in at-risk individuals, has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus.
Market Cap: 2.37 Billion
Primary Exchange: NASDAQ
Website: www.proventionbio.com
Shares Outstanding: 94.8 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.0205302244211463
Sector: Manufacturing
Industry: Medicinal and Botanical Manufacturing
Ethical Flags
Longest drawdown: 1595 trading days
From: 2018-07-24 To: 2019-06-07
Lowest Point:
CHK, DRYS among premarket gainers
via: SeekingAlpha at 2019-06-13 05:19:01:000
DryShips (NASDAQ: DRYS ) +26% after merger offer . More news on: DryShips Inc., Red Robin Gourmet Burgers, Inc., RH, Stocks on the move, Read more … read more...
Provention Bio Announces Termination of Public Offering of Common Stock
via: PR Newswire at 2019-06-13 03:00:00:000
OLDWICK, N.J. , June 13, 2019 /PRNewswire/ --Provention Bio, Inc. (Nasdaq: PRVB) announced today that it has terminated the public offering of common stock previously announced on June 10, 2019 . The termination results from an assessment by the Company's management that current ma… read more...
MT, ZYNE among premarket gainers
via: SeekingAlpha at 2019-06-11 05:21:22:000
Jaguar Health (NASDAQ: JAGX ) +56% as its subsidiary receives preclinical services funded by the National Institute of Allergy and Infectious Diseases. More news on: Jaguar Health, Inc., NovaBay Pharmaceuticals, Inc., Motus GI Holdings, Inc., Stocks on the move, Read more … ... read more...
MT, ZYNE among premarket gainers
via: SeekingAlpha at 2019-06-11 05:21:22:000
Jaguar Health (NASDAQ: JAGX ) +56% as its subsidiary receives preclinical services funded by the National Institute of Allergy and Infectious Diseases. More news on: Jaguar Health, Inc., NovaBay Pharmaceuticals, Inc., Motus GI Holdings, Inc., Stocks on the move, Read more … ... read more...
Provention Bio Announces Proposed Public Offering of Common Stock
via: PR Newswire at 2019-06-10 13:32:00:000
OLDWICK, N.J. , June 10, 2019 /PRNewswire/ --Provention Bio, Inc. (Nasdaq: PRVB) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a registered underwritten public offering of 5,500,000 shares of… read more...
Microcaps dominate midday movers
via: SeekingAlpha at 2019-06-10 08:51:13:000
Gainers: Provention Bio (NASDAQ: PRVB ) +296% . Vuzix Corporation (NASDAQ: VUZI ) +54% . Xynomic Pharmaceuticals Holdings (NASDAQ: XYN ) +46% . Tableau Software (NYSE: DATA ) +35% . Hi-Crush (NYSE: HCR ) +31% . Beyond Meat (NASDAQ: BYND ) +24% . Workhorse Group (NASDAQ: WKHS ) … read more...
MNKD, DATA among premarket gainers
via: SeekingAlpha at 2019-06-10 05:13:59:000
Provention Bio (NASDAQ: PRVB ) +170% on potential of teplizumab to delay diabetes. More news on: Provention Bio, Inc., Tableau Software, Inc., Tilray, Inc., Stocks on the move, Read more … read more...
Provention Bio up 176% premarket on potential of teplizumab to delay diabetes
via: SeekingAlpha at 2019-06-10 04:18:05:000
Thinly traded micro cap Provention Bio (NASDAQ: PRVB ) rockets 176% premarket on robust volume in reaction to its announcement of positive trial data on lead candidate teplizumab (PRV-031), in Phase 3 development for the interception of type 1 diabetes (T1D). The results … read more...
A Single Course of Provention's PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least Two Years
via: PR Newswire at 2019-06-09 09:05:00:000
OLDWICK, N.J. , June 9, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that results from the National Institutes of Health (NIH)-sponsored "At-Risk" Study… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|